Keywords
Kinase, SAR, Bioactivity Database, Dataset, Drug Discovery, Bioactive Molecules, Kinase Knowledgebase, KKB
This article is included in the Cheminformatics gateway.
This article is included in the Data: Use and Reuse collection.
Kinase, SAR, Bioactivity Database, Dataset, Drug Discovery, Bioactive Molecules, Kinase Knowledgebase, KKB
Since their discovery in 1975 by Cohen et al.1, kinases are now one of the most established drug target families, second only to G-protein-coupled receptors (GPCRs). Most progress in kinase research has occurred in the last 25 years including the discovery of many new kinases2,3, identification of new isoforms of pre-existing kinases4,5, elucidation of new biological pathways, and identification of many new kinase-disease associations6,7. While kinases are well-validated anti-cancer targets8–11, kinase inhibitors also have been pursued in cardiovascular12, autoimmune13, inflammatory skin and bowel14, neurodegenerative15, and renal disease programs16. Most small-molecule kinase inhibitors target the ATP binding site of the kinase catalytic domain11. The ATP binding region of the catalytic domain is highly conserved among protein kinases, which has important consequences for drug development. Achieving selectivity of a small molecule inhibitor against kinase off-targets to avoid adverse reactions can be a major hurdle. However, the cross reactivity of many chemotypes can also open opportunities to focus on other closely related kinases. Despite the high degree of conservation in the ATP binding site, reasonably selective inhibitors with favorable pharmacological properties can be developed17. It is now common in discovery programs to profile inhibitors against an extensive set of kinase targets18. These kinase-profiling efforts have generated valuable data, providing insight into selectivity and promiscuity of clinical inhibitors19–21.
Medicinal chemists can benefit significantly from well-curated databases documenting chemical structure(s) with an experimentally measured biological activity. These structure and activity databases or SAR databases help to better understand drug-target interaction, which can assist in the design of potent and selective chemical inhibitors22–25. A well populated, editable, easy to search and flexible SAR database is an integral part of the modern drug design process26. SAR databases provide elementary insights to researchers, including:
(a) Target druggability: known small molecule binders are required to categorize a protein as druggable. High-affinity and non-promiscuous inhibitors are particularly valuable to establish druggability; and can be further validated using structure biology information. In many cases druggability can be inferred for new targets using homology models27 where similarities can be mapped via sequences, pathways or functions. Examples include the Target Informatics Platform (TIP)28 and Modbase29.
(b) Scaffold selectivity: the golden principle that applies is “less selective scaffolds have more undesirable side effects.” A prior knowledge of selectivity profiles can help in making informed decisions on which chemotypes to pursue at the start of discovery programs30. Organizing data by scaffold enables classic SAR analysis in which side-chain moieties can be evaluated and considered or avoided in lead optimization31.
(c) Clinical molecules: it can be very helpful to see scaffold(s) or derivatives under the study of launched drugs. This enables medicinal chemists to associate therapeutic classes with active scaffolds.
(d) Development and validation of computational methods: well-curated datasets are very helpful in the development and refinement of computational methodologies. With a common set of data, computational researchers can also compare and contrast methods, providing additional validation32.
(e) Virtual screening: high-quality, well-curated, standardized and annotated datasets are required to build predictive models for virtual screening as we have shown previously specifically for the Kinase Knowledgebase (KKB) data33.
The KKB is a database of biological activity data, structure-activity relationships, and chemical synthesis data focused on protein kinases. Since its inception in 2001, the KKB has grown steadily with quarterly updates each year. With more than two decades of high quality SAR data, the KKB represents one of the first kinase target specific databases of biological activity and chemical synthesis data from curated scientific literature and patents. The KKB contains a large number of kinase structure-activity data points (>1.8M) reported in peer-reviewed literature covering journals and patents. The data have been curated from over 150 different journals reporting kinase inhibitors with activity data, with leading contributions from J Med Chem, Bioorg Med Chem, Bioorg Med ChemLett and Euro J Med Chem. In addition, the KKB contains data curated from patents/applications from WO, EP and US. The scientific information is curated from the published text using a combination of automatic and manual efforts.
A summary of the first quarter release for year 2016 (Q1-2016) is reported in Table 1. With the Q1-2016 KKB release, there are total of 506 unique kinase targets with over 682K unique small molecules. A listing of few “hot” kinase targets with their inhibitors (data points) is reported in Table 2.
Kinase inhibitors are biologically active small molecules and their activity refers to experimentally measured data on a given kinase target (in enzyme or in cell based assays), using predefined experimental protocols. After curation and standardization, these measured values together with related information are indexed in the KKB. Each inhibitor entered in the KKB carries unique identifiers such as:
(a) Chemical information and biological information: unique structure IDs (MR_ID) are assigned based on unique canonical SMILES. In addition hand-drawn Cartesian coordinates are captured. Chemical compounds are associated with calculated chemical and physical properties.
(b) Biological target and assay protocol: biological targets are annotated by EntrezGeneID, UniProt ID, and HUGO approved names. An assay protocol includes detailed information pertaining to the experiments performed to measure the biological activity for the compound. Each protocol has a descriptive title and a unique set of keywords. Assays are categorized by assay format (biochemical, cell-based, etc.) following standards set forth by BioAssay Ontology (BAO)34,35. Kinase targets are classified by protein and non-protein kinases and protein kinases by the typical domain-based classification into group, family, etc. We are in the process of mapping KKB targets to the Drug Target Ontology (DTO), which is in development.
(c) Experimental bioactivity screening results. A bioactivity data point is a defined result/endpoint of a specified small molecule compound tested in a biological assay. The assay is defined in b); result type/endpoint captured include IC50, Ki, Kd; the vast majority for biochemical and cell-based assays correspond to BAO definitions.
(d) Source reference: bibliographic information and unique identifiers for journal article and patents from which information related to the molecules was extracted include PubMedID, DOI, and standardized patent numbers. For journals, the KKB provides title, authors name, journal-name, volume, issues, and page numbers. For patents their titles, patent or patent application number (along with family members), inventor’s names, assignee names, publication data and priority numbers are provided.
It is observed that a disease type can be related to multiple kinase groups, and several diseases can arise from a common set of kinase group (Table 3)6. In the KKB, kinases are classified by protein and non-protein kinases with several sub-categories such as carbohydrate and lipid kinase and the typical protein kinase groups (such CMGC, CAMK, TK, TKL, RGC, AGC) and further sub-groups such as families. DTO provides a functional and phylogenetic classification of kinase domains to facilitate navigation of kinase drug targets. DTO is developed as part of the Illuminating the Druggable Genome (IDG) project. Here we make datasets freely available for the research community including to support efforts such as IDG. We also offer to run our predictive models built using KKB data to support prioritization of drug targets.
The wealth of kinase inhibitor data presents opportunities for analysis as a whole or by integrating such data into various computational platforms to support development and validation of hypotheses of kinase inhibition. Several years ago, Eidogen-Sertanty made available 3880 pIC50 data points across three kinase targets (ABL1, SRC, and AURKA – validation sets) to foster algorithm development and validation worldwide. With this data note, eight additional targets comprising inhibitors for therapeutically important classes: EGFR, CDK2, ROCK2, MAPK14 and PI3K (class I catalytic) (Table 4) totaling ~258K data points (structure with standard results/endpoints such as IC50, Ki or Kd) and ~76K unique chemical structures now have been made available to further foster worldwide development, validation, and collaborative interaction (see KB_SAR_DATA_F1000.txt and KB_SAR_DATA_F1000.sdf files). These datapoints have been exported from the KKB and survey 1044 articles and 942 patents respectively.
The datasets cover a broad range of biochemical and cell based studies investigating kinase inhibition; and they represent a diverse collection of pharmaceutically active scaffolds. These scaffolds can be easily examined for selectivity and specificity for the given eight kinase targets. Additionally, they can be used to infer novel target-inhibitor relationships for kinases and compounds not included in these subsets.
Bibliographic information is reported in the files ArticleInfo_F1000.txt and PatentInfo_F1000.txt. Experimental procedure along with metadata information for targets including EntrezGeneIDs, assay format/type (biochemical/enzyme, cell based, etc), keywords, species, and cell lines used in cell-based data are stored in AssayProtocols_F1000 (txt and xml attached).
The KKB validation sets have a maximum contribution from EGFR with nearly ~54K inhibitors molecules. This is followed by ~43K inhibitors for MAPK14; CDK2 and PIK3CA each have ~39K inhibitors. Figure 1 depicts data point distributions for each kinase in the attached subset. Moreover, 84% of the data are from biochemical enzyme based assay experiments, and 16% of the data from cell-based assays (in Figure 2). The datapoint measures include IC50, Ki and Kd (Figure 3).
Analysis of ~76K unique molecules for selectivity against targets reveals that ~64K inhibit only one kinase of the eight kinases extracted (Figure 4). Approximately 5K molecules show activity against two kinase targets, and ~3K molecules show activity against three kinases. A total of 79 molecules in the subset have some activity against all the eight kinase targets.
The KKB is available in various formats such as SQL, SDF and IJC format (Instant JChem) as quarterly updates. Two mobile apps, iKinase and iKinasePro25, are also available for download which enable basic search access into KKB content, including kinase inhibitor structures, biological data and references/patents. Simple substructure and exact structure search access into the KKB is also available. We have extracted from the KKB ~258K structure activity data points and ~76K associated unique chemical structures across eight kinase targets and made these data freely available for download within this datanote to foster algorithms development and validation worldwide.
F1000Research: Dataset 1. High quality, small molecule-activity for kinase research, 10.5256/f1000research.8950.d12459136
The work of SCS was supported by grant U54CA189205 (Illuminating the Druggable Genome Knowledge Management Center, IDG-KMC). The IDG-KMC is a component of the Illuminating the Druggable Genome (IDG) project and NIH Common Fund project, awarded by the NCI.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
References
1. Bento AP, Gaulton A, Hersey A, Bellis LJ, et al.: The ChEMBL bioactivity database: an update.Nucleic Acids Res. 2014; 42 (Database issue): D1083-90 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 3 (revision) 26 Oct 16 |
||
Version 2 (revision) 20 Jul 16 |
read | |
Version 1 14 Jun 16 |
read | read |
Click here to access the data.
Spreadsheet data files may not format correctly if your computer is using different default delimiters (symbols used to separate values into separate cells) - a spreadsheet created in one region is sometimes misinterpreted by computers in other regions. You can change the regional settings on your computer so that the spreadsheet can be interpreted correctly.
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)